Clinical Trial Update: Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC [Phase 2]

View source ↗

Summary

Phase II trial evaluating lapatinib plus nab-paclitaxel as first and second line therapy for HER2-positive metastatic breast cancer; study completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lapatinib (Lapatinib)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neoplasms, Breast | Phase 2 | Status: COMPLETED | Results posted: 2011-11-22